Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01453816 |
Recruitment Status :
Withdrawn
(No participants and no longer working with off shore center)
First Posted : October 18, 2011
Last Update Posted : July 21, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The intent of this clinical study is to answer the questions:
- Is the proposed treatment safe
- Is treatment effective in improving the disease pathology of patients with Renal Failure and clinical outcomes
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Failure | Procedure: Harvesting and Isolation of Stem cells | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Renal Artery and Intravenously in Patients With Renal Failure |
Study Start Date : | May 2011 |
Estimated Primary Completion Date : | December 2014 |
Estimated Study Completion Date : | June 2015 |
- Procedure: Harvesting and Isolation of Stem cells
Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
- Significant clinical improvement in serum creatinine and urine output (improvement in measured Glomerular Filtration Rate(GFR) by 50%) [ Time Frame: 3 months ]Compared to baseline
- number of participants with adverse events [ Time Frame: 1 week ]
- Significant clinical improvement in serum creatinine and urine output (improvement in measured Glomerular Filtration Rate(GFR) by 50%) at 6 months [ Time Frame: 6 months ]
- number of participants with adverse events [ Time Frame: 2 weeks ]
- number of participants with adverse events [ Time Frame: 4 weeks ]
- Improvement in renal biopsy measured by the reduction of scarring etc as compared to baseline [ Time Frame: 3 months ]
- Improvement in renal biopsy measured by the reduction of scarring etc as compared to baseline [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and Females between Age 18 and 80 years.
- Chronic Kidney Disease(CKD) patients of stage III, IV, or V
- Patient should be afebrile 24 hours prior to procedure.
- Up to date on all age and gender appropriate cancer screening per American Cancer Society.
Exclusion Criteria:
- Acute Renal Failure
- Severe co-morbidities like cardiac insufficiency, congestive cardiac failure, malignancy, infection, sepsis and bed sores.
- Hemoglobin level below 6g/dl or at the discretion of the physician depending on patient's overall condition.
- Chronic kidney disease due to autoimmune aetiology, connective tissue disease, amyloidosis and storage disorders.
- Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
- Life expectancy < 6 months due to concomitant illnesses.
- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
- Active infectious disease. Patients known to have tested positive for Human immunodeficiency virus (HIV), Human T-lymphotropic virus(HTLV), Hepatitis B (HBV),Hepatitis C (HCV), Cytomegalovirus (CMV) and/or syphilis will be evaluated by an expert as to patient eligibility based on the patient's infectious status
- Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
- Patients on chronic immunosuppressive transplant therapy
- Systolic blood pressure (supine) ≤90 mmHg or greater than 200mmHg
- Resting heart rate > 100 bpm;
- Active clinical infection within one week of enrollment.
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
- Unwilling and/or not able to give written informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01453816
Mexico | |
Hospital Angeles | |
Tijuana, Baja California, Mexico, 22010 |
Principal Investigator: | Rigoberto Pallares, MD | Instituto de Medicina Regenerativa |
Responsible Party: | Ageless Regenerative Institute |
ClinicalTrials.gov Identifier: | NCT01453816 |
Other Study ID Numbers: |
ADI-ME-RF-001 |
First Posted: | October 18, 2011 Key Record Dates |
Last Update Posted: | July 21, 2017 |
Last Verified: | July 2017 |
Renal insufficiency kidney failure |
Renal Insufficiency Kidney Diseases Urologic Diseases |